CEO Executive AssistantPharma CEO time management for health economics strategy is an area where many pharmaceutical executives recognize the importance but struggle to engage at the right organizational level. Health economics and outcomes research (HEOR) is a discipline that sits at the intersection of clinical evidence, economic modeling, and payer decision-making, and the quality of a company’s HEOR strategy directly determines how well the clinical benefits demonstrated in trials translate into the market access outcomes that generate commercial returns.
The CEO who treats HEOR as a technical function fully managed by health economists and market access teams may find that the company’s most valuable clinical assets are chronically underreimbursed because the economic value story is not being told in the terms and with the evidence rigor that payers and HTA bodies require. Pharma CEO time management health economics is about engaging with HEOR strategy at the level that connects economic evidence generation to commercial outcomes, without requiring the CEO to become a health economist.
The Strategic Role of Health Economics in Value Creation
Health economics strategy creates commercial value through several mechanisms that the CEO should understand at a strategic level. Cost-effectiveness modeling that demonstrates a new therapy’s value relative to existing treatment options, when conducted rigorously and presented to payers in the context of their specific formulary and patient population, can support premium pricing and preferential formulary placement that significantly affects peak sales potential.
Budget impact modeling that quantifies how adopting a new therapy affects a payer’s total healthcare spend for a specific patient population enables payers to plan for formulary changes and supports their coverage decisions with financial predictability rather than requiring them to make coverage decisions under cost uncertainty. Health outcomes data that documents how patients who receive the new therapy fare in terms of hospitalizations avoided, quality-adjusted life years gained, and productivity maintained provides the population health evidence that value-based contracting requires.
Each of these HEOR outputs requires deliberate investment in study design, data collection, and modeling methodology that must begin years before commercial launch to be available when payer engagement begins. The CEO who does not engage with HEOR strategy early enough to influence this investment timing will discover, at the pre-launch planning stage, that the economic evidence package is inadequate to support the market access strategy the commercial team is planning.
HEOR as Part of Development Governance
The most impactful CEO investment in health economics strategy is integrating HEOR planning into clinical development governance before Phase 3 trial design is finalized. This integration requires an organizational structure where the HEOR team, typically within medical affairs or market access, has input into trial design decisions that affect the economic evidence that can be generated from the trial data.
Clinical trial design decisions with HEOR implications include the selection of patient-reported outcome measures included in the trial, the collection of healthcare resource utilization data that allows cost-effectiveness modeling, the trial comparator chosen (which determines the economic reference case for cost-effectiveness analysis), and the trial duration (which affects the observation period for health outcomes relevant to the economic model).
The CEO’s governance role is ensuring that the organizational process for Phase 3 trial design includes HEOR input as a standard step, with the same weight given to HEOR evidence requirements as to regulatory and clinical requirements. A Phase 3 trial design review that does not include explicit HEOR planning is missing the opportunity to generate the economic evidence that market access depends on.
For the market access strategy that deploys HEOR evidence in payer negotiations, see market access strategy. For the payer strategy that frames HEOR evidence in payer-relevant terms, see payer strategy oversight.
Value Dossier Development and CEO Strategic Input
The value dossier, the comprehensive documentation of a product’s clinical, economic, and patient-reported evidence prepared for HTA submissions and payer negotiations, is the primary output of the HEOR function and the document that most directly determines reimbursement outcomes in major markets. The CEO’s relationship to value dossier development is at the strategic input stage rather than the content development stage: providing the commercial and strategic context that determines which evidence dimensions the dossier should emphasize and how the economic argument should be framed.
The CEO’s strategic input to value dossier development includes: what is the primary value proposition the company wants payers to understand about this product, which patient population segments represent the greatest clinical and economic value, and what competitive products or treatment pathways define the economic comparison context? These strategic inputs shape the HEOR team’s modeling assumptions and the value narrative that the dossier presents.
A value dossier review meeting with the CEO at the draft stage, sixty to ninety minutes, allows the CEO to confirm that the economic argument reflects the strategic commercial positioning and to identify any gaps between the evidence available and the evidence the payer negotiations will require. This review occurs well before the dossier is finalized, allowing time to address identified gaps through additional analyses or supplementary data collection.
Regional Health Economic Variation
A dimension of HEOR governance that requires CEO strategic awareness is the significant variation in health economic methodology and evidence requirements across major market geographies. The UK’s NICE (National Institute for Health and Care Excellence), Germany’s G-BA (Gemeinsamer Bundesausschuss), France’s HAS (Haute Autorité de Santé), and US payer organizations all evaluate economic evidence through different methodological frameworks and apply different thresholds for cost-effectiveness acceptability.
A HEOR strategy that generates evidence optimized for one market’s methodology may be inadequate for another market’s requirements. The CEO’s governance role is ensuring that the HEOR strategy is developed with geographic specificity from the outset, not adapted for each market as a sequential afterthought. This requires HEOR investment decisions that explicitly prioritize the markets where economic evidence quality will most significantly affect access outcomes.
For multinational pharmaceutical companies, the CEO should review the geographic prioritization of HEOR investment annually, confirming that the evidence generation plan is aligned with the commercial priority markets and the specific HTA and payer evidence requirements of those markets.
Real-World Evidence and HEOR Integration
The integration of real-world evidence (RWE) with HEOR strategy is a CEO-level governance consideration because the most compelling economic value stories for payers often require both the efficacy evidence from clinical trials and the effectiveness evidence from real-world clinical practice. RWE that demonstrates that patients who receive the product in routine clinical practice achieve outcomes consistent with or better than clinical trial outcomes substantially strengthens the economic value argument.
The CEO’s HEOR-RWE integration governance role is ensuring that RWE study design decisions, made within the RWE strategy governance process, explicitly consider the HEOR modeling implications of the data generated. A real-world evidence study that captures healthcare resource utilization data provides inputs for real-world cost-effectiveness modeling that enhances the economic value story for payers. A real-world evidence study that captures only clinical outcome data without economic data produces a weaker economic evidence package.
Research from McKinsey on health economics and pharmaceutical market access highlights that pharmaceutical companies with integrated HEOR strategies that span clinical development, real-world evidence, and active payer engagement achieve better reimbursement outcomes for their products in competitive markets, with CEOs who engage in HEOR strategy governance being the most significant predictor of organizational investment adequacy.
Conclusion
Pharma CEO time management for health economics strategy is about engaging with HEOR investment decisions at the development planning stage, integrating HEOR input into clinical trial design governance, providing strategic commercial input to value dossier development, ensuring geographic specificity in evidence generation investment, and integrating RWE and HEOR strategies into a coherent economic evidence program. The CEO who governs health economics strategy with this level of engagement builds the evidence infrastructure that translates clinical trial success into market access outcomes. Without that evidence infrastructure, even the most clinically compelling products may be chronically underreimbursed, delivering a fraction of the commercial value that the clinical evidence base supports.